BullFrog AI Holdings Inc. (NASDAQ:BFRG) on Wednesday introduced bfARENAS, a scenario-based decision engine.

The engine aims at improving pharmaceutical portfolio strategy and clinical trial design, as the company looks to address inefficiencies in drug development driven by high uncertainty and failure rates.

BullFrog AI will host a webinar in partnership with Xtalks Life Sciences on March 27, 2026, to showcase bfARENAS and its applications in clinical and portfolio strategy.

Addressing High Failure Rates In Clinical Trials

The company said that new platform is designed to help biotech and pharmaceutical organizations navigate complex R&D environments, where long timelines, limited capital, and high failure rates remain persistent challenges.

Vin Singh, founder and CEO of BullFrog AI, said many companies still struggle to convert growing volumes of data into consistent and transparent decision-making frameworks. He noted that this often leads to inefficient capital allocation across development programs.

Singh added that bfARENAS introduces a structured approach by treating strategic scenarios as core inputs, allowing organizations to compare outcomes across multiple potential futures rather than relying on static assumptions.

Scenario-Based Approach To Portfolio Strategy

Unlike traditional machine learning tools that reduce decisions to fixed scores or weightings, bfARENAS evaluates drug programs, biomarkers, indications, and trial designs through direct comparisons across varying strategic conditions.

The platform enables companies to test decisions under scenarios such as capital constraints, global expansion strategies or region-specific priorities, helping identify programs that remain viable across multiple environments.

Expanding End-To-End AI Workflow

bfARENAS adds a strategic decision-making layer to BullFrog AI's existing products, bfPREP and bfLEAP, completing its end-to-end AI-driven workflow.

The system integrates with BullFrog Data Networks, allowing users to move from data processing and causal analysis to portfolio-level decision support within a single platform.

Key capabilities include preserving portfolio diversity, identifying high-performing assets across scenarios, and enabling explainable, trackable decision-making processes.

The company said the platform is intended to support high-stakes R&D decisions, ultimately helping accelerate the development of new therapeutics while balancing risk and resource allocation.

In January, BullFrog AI highlighted the presentation of data derived from the use of the company’s proprietary platform, bfLEAP, with pancreatic cancer trial data to identify an almost three times increase in mean survival from the control to treatment arms.

BFRG Stock Price Activity: Bullfrog AI shares were up 3.13% at $0.58 during premarket trading on Wednesday, according to Benzinga Pro data.

Image via Shutterstock